Private Eye

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Multiple insider buying at Antibe Therapeutics (T:ATE)

Updated Monday Jun 07, 2021 02:26 AM EDT

John Lawrence Wallace, a Senior Officer, Director and 10% Holder, acquired 1,496,631 Common Shares on a direct ownership basis at a price of $4.424 through a private transaction on June 2nd, 2021. The insider also acquired 330,098 Common Shares on a control or direction basis for registered holder AltaPharm International Inc. at a price of $4.424 through a private transaction on June 2nd, 2021. This represents a $8,080,536 investment into the company's shares and an account share holdings change of greater than 100%.

Daniel Marcel Legault, CEO, Director and 10% Holder, acquired 596,340 Common Shares on a direct ownership basis at a price of $4.424 through a private transaction on June 2nd, 2021. The insider also acquired 46,458 Common Shares on a control or direction basis for registered holder Schmed Enterprises Inc. at a price of $4.424 through a private transaction on June 2nd, 2021. This represents a $2,843,417 investment into the company's shares and an account share holdings change of greater than 100%.

Roderick John Flower, a Director, acquired 69,377 Common Shares on a direct ownership basis at a price of $4.424 through a private transaction on June 2nd, 2021. This represents a $306,889 investment into the company's shares and an account share holdings change of greater than 100%.

Alain Wilson, CFO, acquired 41,296 Common Shares on a control or direction basis for registered holder The Elegen Group Inc. at a price of $4.424 through a private transaction on June 2nd, 2021. This represents a $182,673 investment into the company's shares and an account share holdings change of greater than 100%.

David James Vaughan, a Senior Officer, acquired 17,551 Common Shares on a direct ownership basis at a price of $4.424 through a private transaction on June 2nd, 2021. This represents a $77,637 investment into the company's shares and an account share holdings change of greater than 100%.

Antibe Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
Rain
N/A
Rain
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to Antibe Therapeutics Inc. (ATE)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $ATE.CA

  • No tweets found

Stocktwits